ABT stock verdict - Growth
ABT
ABBOTT LABORATORIES
GROWTHHealthcare
$101.29
Buy
$101.29
Heavy$77.27Buy$103.03Fair$128.79Exit$154.55
VALUE67
GROWTH31
QUALITY87
TECHNICAL—
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Trades 21% below the model's fair value ($128.79)
- Balance sheet holds net cash (cash exceeds total debt)
- Converts 16% of revenue into free cash flow
- High gross margin of 56% (3-yr avg)
CONS
- TTM EPS fell 51.3% year-over-year
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 151% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on ABT. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is ABT rated Growth?
ABT (ABBOTT LABORATORIES) is rated Growth because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Buy. Trades 21% below the model's fair value ($128.79) and Balance sheet holds net cash (cash exceeds total debt)
Is ABT overvalued right now?
ABT is trading at $101.29 versus an estimated fair value of $128.79. That puts the stock in growth territory on this framework. TTM EPS fell 51.3% year-over-year
What should I watch before acting on ABT?
Watch the trust score of 100, the earnings-quality checks, and any red flags. TTM EPS fell 51.3% year-over-year